Yayın:
Determining the accuracy of next generation sequencing based copy number variation analysis in Hereditary Breast and Ovarian Cancer

dc.contributor.authorAgaoglu, Nihat Bugra
dc.contributor.authorUnal, Busra
dc.contributor.authorAkgun Dogan, Ozlem
dc.contributor.authorZolfagharian, Payam
dc.contributor.authorSharifli, Pari
dc.contributor.authorKarakurt, Aylin
dc.contributor.authorCan Senay, Burak
dc.contributor.authorKizilboga, Tugba
dc.contributor.authorYildiz, Jale
dc.contributor.authorDinler Doganay, Gizem
dc.contributor.authorDoganay, Levent
dc.contributor.ituauthorDinler, Doğanay Gizem
dc.date.accessioned2026-01-25T05:16:42Z
dc.date.issued2022-02-01
dc.description.abstractCopy number variations (CNVs) are commonly associated with malignancies, including hereditary breast and ovarian cancers. Next generation sequencing (NGS) provides solutions for CNV detection in a single run. This study aimed to compare the accuracy of CNV detection by NGS analyzing tool against Multiplex Ligation Dependent Probe Amplification (MLPA).In total, 1276 cases were studied by targeted NGS panels and 691 cases (61 calls in 58 NGS-CNV positive and 633 NGS-CNV negative cases) were validated by MLPA.Twenty-eight (46%) NGS-CNV positive calls were consistent, whereas 33 (54%) calls showed discordance with MLPA. Two cases were detected as SNV by the NGS and CNV by the MLPA analysis. In total, 2% of the cases showed an MLPA confirmed CNV region in BRCA1/2. The results of this study showed that despite the high false positive call rate of the NGS-CNV algorithm, there were no false negative calls. The cases that were determined to be negative by the NGS and positive by the MLPA were actually carrying SNVs that were located on the MLPA probe binding sites.The diagnostic performance of NGS-CNV analysis is promising; however, the need for confirmation by different methods remains.
dc.description.urihttps://doi.org/10.1080/14737159.2022.2048373
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/35240897
dc.identifier.doi10.1080/14737159.2022.2048373
dc.identifier.eissn1744-8352
dc.identifier.endpage246
dc.identifier.issn1473-7159
dc.identifier.openairedoi_dedup___::6b672068740f62f812e2e7294cb73860
dc.identifier.orcid0000-0002-9336-0552
dc.identifier.orcid0000-0002-2056-2604
dc.identifier.orcid0000-0002-8310-4053
dc.identifier.orcid0000-0003-3115-2261
dc.identifier.orcid0000-0003-3563-5973
dc.identifier.orcid0000-0002-4755-6669
dc.identifier.orcid0000-0002-8153-4228
dc.identifier.orcid0000-0001-5431-9461
dc.identifier.orcid0000-0002-4950-570x
dc.identifier.orcid0000-0002-3586-1287
dc.identifier.orcid0000-0002-2263-6689
dc.identifier.startpage239
dc.identifier.urihttps://hdl.handle.net/11527/46796
dc.identifier.volume22
dc.language.isoeng
dc.publisherInforma UK Limited
dc.relation.ispartofExpert Review of Molecular Diagnostics
dc.sdg.typeGoal 3: Good Health and Well-being
dc.subjectOvarian Neoplasms
dc.subjectDNA Copy Number Variations
dc.subjectHigh-Throughput Nucleotide Sequencing
dc.subjectHumans
dc.subjectCarcinoma, Ovarian Epithelial
dc.subjectMultiplex Polymerase Chain Reaction
dc.titleDetermining the accuracy of next generation sequencing based copy number variation analysis in Hereditary Breast and Ovarian Cancer
dc.typeArticle
dspace.entity.typePublication
person.identifier.orcid0000-0002-3586-1287

Dosyalar

Koleksiyonlar